Nepal vs Small island developing States (SIDS): Percentage of bloodstream infection due to Escherichia coli resistant
Nepal
77.1%
in 2022
Small island developing States (SIDS)
50.0%
in 2022
Nepal rank
5th
Small island developing States (SIDS) rank
8th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Nepal
- Small island developing States (SIDS)
How they compare
Nepal currently reports 77.1% against 50.0% in Small island developing States (SIDS), a difference of 27.1%.
That makes Nepal's figure about 1.5 times Small island developing States (SIDS)'s.
Across all 5 years both countries report, Nepal has been ahead every year.
Nepal ranks 5th and Small island developing States (SIDS) ranks 8th of 50 countries.
Nepal has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Nepal | Small island developing States (SIDS) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71.3% | 45.9% | 25.4% | Nepal |
| 2020s | 76.8% | 43.4% | 33.4% | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Nepal or Small island developing States (SIDS)?
- Nepal, at 77.1% against 50.0% in Small island developing States (SIDS) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Nepal and Small island developing States (SIDS)?
- 27.1%, with Nepal ahead.
- How many years of comparable data are there for Nepal and Small island developing States (SIDS)?
- 5 years are reported by both, from 2018 to 2022.
- How do Nepal and Small island developing States (SIDS) rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Nepal ranks 5th and Small island developing States (SIDS) ranks 8th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.